10% growth YoY 2 years in a row is truly awful growth.
The MC v ARR still make this an interesting proposition that I remain to follow, but I can't see institutional investors wanting to jump on board to an EX platform that couldn't grow in dream conditions.
They spend the past 2 years changing their sales mode and achieved F-All. Where do they go from here?
- Forums
- ASX - By Stock
- Ann: FY22 Q3 Quarterly Activities Report and Appendix 4C
10% growth YoY 2 years in a row is truly awful growth.The MC v...
-
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LVT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online